<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34426551</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study.</ArticleTitle><Pagination><StartPage>e803</StartPage><EndPage>e813</EndPage><MedlinePgn>e803-e813</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000012367</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate progressive cerebral degeneration in amyotrophic lateral sclerosis (ALS) by assessing alterations in <i>N</i>-acetylaspartate (NAA) ratios in the motor and prefrontal cortex within clinical subgroups of ALS.</AbstractText><AbstractText Label="METHODS">Seventy-six patients with ALS and 59 healthy controls were enrolled in a prospective, longitudinal, multicenter study in the Canadian ALS Neuroimaging Consortium. Participants underwent serial clinical evaluations and magnetic resonance spectroscopy at baseline and 4 and 8 months using a harmonized protocol across 5 centers. NAA ratios were quantified in the motor cortex and prefrontal cortex. Patients were stratified into subgroups based on disease progression rate, upper motor neuron (UMN) signs, and cognitive status. Linear mixed models were used for baseline and longitudinal comparisons of NAA metabolite ratios.</AbstractText><AbstractText Label="RESULTS">Patients with ALS had reduced NAA ratios in the motor cortex at baseline (<i>p</i> &lt; 0.001). Ratios were lower in those with more rapid disease progression and greater UMN signs (<i>p</i> &lt; 0.05). A longitudinal decline in NAA ratios was observed in the motor cortex in the rapidly progressing (<i>p</i> &lt; 0.01) and high UMN burden (<i>p</i> &lt; 0.01) cohorts. The severity of UMN signs did not change significantly over time. NAA ratios were reduced in the prefrontal cortex only in cognitively impaired patients (<i>p</i> &lt; 0.05<i>)</i>; prefrontal cortex metabolites did not change over time.</AbstractText><AbstractText Label="CONCLUSIONS">Progressive degeneration of the motor cortex in ALS is associated with more aggressive clinical presentations. These findings provide biological evidence of variable spatial and temporal cerebral degeneration linked to the disease heterogeneity of ALS. The use of standardized imaging protocols may have a role in clinical trials for patient selection or subgrouping.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that MRS NAA metabolite ratios of the motor cortex are associated with more rapid disease progression and greater UMN signs in patients with ALS.</AbstractText><AbstractText Label="TRIAL REGISTRATION INFORMATION">ClinicalTrials.gov Identifier: NCT02405182.</AbstractText><CopyrightInformation>&#xa9; 2021 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4975-2970</Identifier><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada. sanjay.kalra@ualberta.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishaque</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Ojas</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanstock</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seres</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eurich</LastName><ForeName>Dean T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Collin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briemberg</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frayne</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0358-1210</Identifier><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Simon J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada. sanjay.kalra@ualberta.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02405182</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34426551</ArticleId><ArticleId IdType="pmc">PMC8397589</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012367</ArticleId><ArticleId IdType="pii">WNL.0000000000012367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beghi E, Mennini T, Bendotti C, et al. . The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185-3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S. Magnetic resonance spectroscopy in ALS. Front Neurol. 2019;10:482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524558</ArticleId><ArticleId IdType="pubmed">31133975</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhy J, Miller RG, Rule R, et al. . Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology. 2002;58(5):773-779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733360</ArticleId><ArticleId IdType="pubmed">11889242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Ulug AM, Pullman SL, et al. . Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68(17):1402-1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Pullman SL, Shungu DC, et al. . Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology. 2004;62(10):1753-1757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159473</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohl C, Block W, Tr&#xe4;ber F, et al. . Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci. 2001;190(1-2):21-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11574102</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Takanashi M, Watanabe Y, et al. . Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology. 2001;43(7):537-541.</Citation><ArticleIdList><ArticleId IdType="pubmed">11512581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Mot Neuron Disord. 2004;5(3):141-149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744639</ArticleId><ArticleId IdType="pubmed">15512902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudharshan N, Hanstock C, Hui B, Pyra T, Johnston W, Kalra S. Degeneration of the mid-cingulate cortex in amyotrophic lateral sclerosis detected in vivo with MR spectroscopy. AJNR Am J Neuroradiol. 2011;32(2):403-407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965735</ArticleId><ArticleId IdType="pubmed">21087934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Poptani H, Woo JH, et al. . Amyotrophic lateral sclerosis: diffusion-tensor and chemical shift MR imaging at 3.0 T. Radiology. 2006;239(3):831-838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16641339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology. 1999;212(3):763-769.</Citation><ArticleIdList><ArticleId IdType="pubmed">10478245</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Elman L, McCluskey L, et al. . Frontal lobe abnormalities on MRS correlate with poor letter fluency in ALS. Neurology. 2012;79(6):583-588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413764</ArticleId><ArticleId IdType="pubmed">22843269</ArticleId></ArticleIdList></Reference><Reference><Citation>Usman U, Choi C, Camicioli R, et al. . Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study. AJNR Am J Neuroradiol. 2011;32(9):1677-1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965387</ArticleId><ArticleId IdType="pubmed">21778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis: a longitudinal proton magnetic resonance spectroscopy study. J Neurol. 2007;254(8):1099-1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431700</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Graaff MM, Lavini C, Akkerman EM, et al. . MR spectroscopy findings in early stages of motor neuron disease. Am J Neuroradiol. 2010;31(10):1799-1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7964017</ArticleId><ArticleId IdType="pubmed">20801763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjay Kalra A, Khan M, Barlow L, et al. . The Canadian ALS Neuroimaging Consortium (CALSNIC): a multicentre platform for standardized imaging and clinical studies in ALS. medRxiv. 2020. Accessed July 16, 2020. 10.1101/2020.07.10.20142679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.10.20142679</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293-299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):9-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava O, Hanstock C, Chenji S, et al. . Cerebral degeneration in amyotrophic lateral sclerosis: a prospective multicenter magnetic resonance spectroscopy study. Neurol Clin Pract. 2019;9(5):400-407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814429</ArticleId><ArticleId IdType="pubmed">31750025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284-290.</Citation></Reference><Reference><Citation>Selya AS, Rose JS, Dierker LC, Hedeker D, Mermelstein RJ. A practical guide to calculating Cohen's f(2), a measure of local effect size, from PROC MIXED. Front Psychol. 2012;3:111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328081</ArticleId><ArticleId IdType="pubmed">22529829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S, Hanstock CC, Martin WR, Allen PS, Johnston WS. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol. 2006;63(8):1144-1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(11):1253-1255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077382</ArticleId><ArticleId IdType="pubmed">16835288</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Jiang R, Yi X, Zhu W, Bu B. Role of diffusion tensor imaging or magnetic resonance spectroscopy in the diagnosis and disability assessment of amyotrophic lateral sclerosis. J Neurol Sci. 2015;348(1-2):206-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">25524526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyra T, Hui B, Hanstock C, et al. . Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1-2):157-165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19242831</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora M, Kumar S, Sharma S, Sharma S, Makhaik S, Sood RG. Advanced magnetic resonance neuroimaging in bulbar and limb onset early amyotrophic lateral sclerosis. J Neurosci Rural Pract. 2016;7(1):102-108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750305</ArticleId><ArticleId IdType="pubmed">26933355</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Xu M, Triantafyllou C, et al. . Ultra high-field (7Tesla) magnetic resonance spectroscopy in amyotrophic lateral sclerosis. PLoS One. 2017;12(5):e0177680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5428977</ArticleId><ArticleId IdType="pubmed">28498852</ArticleId></ArticleIdList></Reference><Reference><Citation>d'Ambrosio A, Gallo A, Trojsi F, et al. . Frontotemporal cortical thinning in amyotrophic lateral sclerosis. Am J Neuroradiol. 2014;35(2):304-310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965753</ArticleId><ArticleId IdType="pubmed">24113470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzapesa DM, D'Errico E, Tortelli R, et al. . Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS One. 2013;8(1):e80748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835750</ArticleId><ArticleId IdType="pubmed">24278317</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Valsasina P, Riva N, et al. . The cortical signature of amyotrophic lateral sclerosis. PLoS One. 2012;7(8):e42816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412820</ArticleId><ArticleId IdType="pubmed">22880116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S, M&#xfc;ller HP, Ishaque A, et al. . A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS. Neurology. 2020;95(8):e943-e952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668555</ArticleId><ArticleId IdType="pubmed">32646955</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol Lancet Neurol. 2009;8(1):94-109.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong I, Deelchand DK, Eberly LE, et al. . Neurochemical correlates of functional decline in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;0(3):1-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467050</ArticleId><ArticleId IdType="pubmed">30467209</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Gorno-Tempini ML, Pagani E, et al. . Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler. 2009;10(3):168-174.</Citation><ArticleIdList><ArticleId IdType="pubmed">19058055</ArticleId></ArticleIdList></Reference><Reference><Citation>Block W, Karitzky J, Tr&#xe4;ber F, et al. . Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. 1998;55(7):931-936.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678310</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng H-J, Walhout R, et al. . Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis. Neurology. 2020;94(24):e2592-e2604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455328</ArticleId><ArticleId IdType="pubmed">32414878</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C. A prospective study of cognitive impairment in ALS. Neurology 1999;53(30):1665-1670.</Citation><ArticleIdList><ArticleId IdType="pubmed">10563610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanstock C, Sun K, Choi C, et al. . Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. Amyotroph Lateral Scler Front Degener. 2020;21(3-4):246-251.</Citation><ArticleIdList><ArticleId IdType="pubmed">32067510</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4(7):605-618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305182</ArticleId><ArticleId IdType="pubmed">28203356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayed N, Modrego PJ, Medrano J. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain: the LCModel versus the manufacturer software. Neurol Res. 2009;31(5):472-477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19215666</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009;10(5-6):324-331.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922119</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal imaging in C9orf72 mutation carriers: relationship to phenotype. Neuroimage Clin. 2016;12:1035-1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153604</ArticleId><ArticleId IdType="pubmed">27995069</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>